Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Strength Training for Skeletal Muscle Adaptation After Stroke

7 de junio de 2018 actualizado por: VA Office of Research and Development
Chronically disabled stroke survivors experience accelerated skeletal muscle atrophy and other detrimental changes to muscle and surrounding tissues on the paretic side. This unilateral tissue-level damage contributes to worsening disability and insulin resistance. This VA Merit Award will advance the investigators' understanding of the potential for strength training (ST) to reverse stroke-related muscle abnormalities to improve metabolic health, strength, and function. It will be the first study to thoroughly investigate the effects of ST on muscle atrophy, intramuscular fat, muscle fiber characteristics, capillary density and insulin sensitivity after stroke.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

This study investigates the hypothesis that a novel, high intensity, high repetition ST program will improve abnormalities in paretic and non-paretic leg muscle volume and composition compared to an attention-matched control regimen of supervised stretching over a 3-month intervention period in those disabled by stroke. The investigators further hypothesize that ST-induced skeletal muscle adaptation will translate into improved insulin sensitivity, strength, and function in this population. The specific objectives are to: 1) Determine the effects ST compared to a control intervention on paretic and non-paretic abnormalities in skeletal muscle volume, intramuscular fat, muscle fiber distribution, muscle capillary density, and muscle inflammation in chronically disabled stroke survivors. 2) Determine the effects ST compared to a control intervention on insulin sensitivity in stroke survivors, and whether structural and cellular skeletal muscle mechanisms contribute to improvements in insulin sensitivity after ST. 3) Determine the effects ST compared to a control intervention on physical function (strength, walking speed and balance) in stroke survivors, and whether structural skeletal muscle mechanisms predict ST-induced functional improvement.

The project design consists of 4 phases over 5 months for stroke participants enrolled in either of the two intervention arms (ST vs. CONTROL). During phase 1 the investigators will screen and consent chronic stroke patients with residual gait deficits. Phase 2 (3 weeks) will consist of baseline testing that includes dual energy X-ray absorptiometry (DEXA) scanning, bilateral CT scanning of the legs, bilateral vastus lateralis muscle biopsies, strength testing, timed walks, balance measurements, oral glucose tolerance testing, and hyperglycemic clamp testing. Following completion of baseline testing, volunteers are to be randomized to ST or the CONTROL group. Phase 3 (Intervention Phase, 3 months) will begin with 2 sessions of acclimatization for those assigned to the ST group. ST will then be progressed to 2 sets of 20 repetitions on each leg on each machine (Keiser Leg Press, Leg Extension, Leg Curl) with gradual increases in resistance over 3 months. Those in the CONTROL group will receive equal exposure to health care personnel in the Baltimore VA Exercise facility, performing a full battery of upper and lower body passive and active stretching exercises at each intervention session. In Phase 4 all baseline testing and laboratory analyses will be repeated.

Developing evidence-based therapies to combat skeletal muscle deterioration is highly relevant for chronically disabled stoke survivors. There is mounting evidence that current models of post-stroke rehabilitation are not optimal for maximizing recovery of muscle mass, strength, and metabolic health. The proposed research will develop new insight into the utility of progressive ST for reversing detrimental changes to gross muscle composition, muscle molecular phenotype, muscle inflammation, and muscle capillarization. Changes to any or all of these muscle parameters should have measurable impact on both whole body insulin sensitivity and function. Collectively, the results from this trial may change the current standard of care for stroke survivors by providing evidenced reasons for augmenting physical therapists' treatments, allowing more intense and diverse therapy sessions for maintenance of skeletal muscle.

Tipo de estudio

Intervencionista

Inscripción (Actual)

38

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Stroke greater than 6 months prior with residual hemiparetic gait in women or men aged 40-85 years
  • Completion of all regular post-stroke physical therapy
  • Adequate language and neurocognitive function to participate in testing and training and to give adequate informed consent

Exclusion Criteria:

  • Alcohol consumption greater than 3 oz. liquor, or 3 x 4 oz glasses of wine, or 3 x 12 oz. beers per day, by self-report
  • clinical history of:

    • unstable angina
    • recent (less than 3 months) myocardial infarction or congestive heart failure (NYHA category II)
    • hemodynamically significant valvular dysfunction
    • peripheral arterial occlusive disease (PAOD) with claudication
    • major orthopedic, chronic pain, or non-stroke neuromuscular disorders restricting exercise
    • pulmonary or renal failure
    • poorly controlled hypertension (greater than 190/110)
    • recent hospitalization for severe disease or surgery
    • severe or global receptive aphasia which confounds reliable testing and training
  • Allergy to lidocaine
  • Known muscle disorder
  • Taking Coumadin or Lovenox (contraindication for muscle biopsies)
  • Dementia
  • Untreated major depression

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1
Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
Comparador activo: Arm 2
Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
3x per week upper and lower body stretching mixed with active and passive range of motion exercises

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side)
Periodo de tiempo: Baseline, 3 months
Baseline, 3 months
Change in 1-RM Muscle Strength (Leg Press, Non-Paretic Side)
Periodo de tiempo: Baseline, 3 months
Baseline, 3 months
Change in 1-RM Muscle Strength (Leg Extension, Paretic Side)
Periodo de tiempo: Baseline, 3 Months
Baseline, 3 Months
Change in 1-RM Muscle Strength (Leg Extension, Non-Paretic Side)
Periodo de tiempo: Baseline, 3 Months
Baseline, 3 Months
Change in Leg Muscle Endurance (Paretic Side)
Periodo de tiempo: Baseline, 3 Months
Tests how training impacts the total number of submaximal repetitions a participant can perform according to standardized cadence (at the same absolute level of resistance, pre and post).
Baseline, 3 Months
Change in Leg Muscle Endurance (Non-Paretic Side)
Periodo de tiempo: Baseline, 3 months
Tests how training impacts the total number of submaximal repetitions a participant can perform according to standardized cadence (at the same absolute level of resistance, pre and post).
Baseline, 3 months
Change in 6-minute Walk Distance
Periodo de tiempo: Baseline, 3 Months
Baseline, 3 Months
Change in 10 Meter Walking Speed (Self-Selected)
Periodo de tiempo: Baseline, 3 months
Baseline, 3 months
Change in 10 Meter Walking Speed (Fastest)
Periodo de tiempo: Baseline, 3 Months
Baseline, 3 Months
Change in Peak Aerobic Capacity (VO2 Peak)
Periodo de tiempo: Baseline, 3 Months
Baseline, 3 Months
Change in Berg Balance Scale
Periodo de tiempo: Baseline, 3 months
This measure is a 14 item scale, with each item scored (0-4) and summed for a maximum score of 56 points. Range is 0-56 and higher values represent a better outcome.
Baseline, 3 months
Change in Paretic Limb Step Time (Self-Selected)
Periodo de tiempo: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Paretic Limb Step Time (Fastest)
Periodo de tiempo: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Non-Paretic Limb Step Time (Self-Selected)
Periodo de tiempo: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Non-Paretic Limb Step Time (Fastest)
Periodo de tiempo: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Paretic Limb Step Length (Self-Selected)
Periodo de tiempo: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Paretic Limb Step Length (Fastest)
Periodo de tiempo: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Non-Paretic Limb Step Length (Self-Selected)
Periodo de tiempo: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Non-Paretic Limb Step Length (Fastest)
Periodo de tiempo: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2009

Finalización primaria (Actual)

31 de agosto de 2013

Finalización del estudio (Actual)

6 de junio de 2018

Fechas de registro del estudio

Enviado por primera vez

22 de enero de 2009

Primero enviado que cumplió con los criterios de control de calidad

22 de enero de 2009

Publicado por primera vez (Estimar)

23 de enero de 2009

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de julio de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

7 de junio de 2018

Última verificación

1 de junio de 2018

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

No

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir